Skip Nav Destination
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection
Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
G6PD deficiency, absence of α-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia
Issue Archive
November 15 2008
Table of Contents
INSIDE BLOOD
ASH 50TH ANNIVERSARY REVIEWS
CHEMOKINES, CYTOKINES, AND INTERLEUKINS
CLINICAL TRIALS AND OBSERVATIONS
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
Clinical Trials & Observations
Timothy P. Hughes,Susan Branford,Deborah L. White,John Reynolds,Rachel Koelmeyer,John F. Seymour,Kerry Taylor,Chris Arthur,Anthony Schwarer,James Morton,Julian Cooney,Michael F. Leahy,Philip Rowlings,John Catalano,Mark Hertzberg,Robin Filshie,Anthony K. Mills,Keith Fay,Simon Durrant,Henry Januszewicz,David Joske,Craig Underhill,Scott Dunkley,Kevin Lynch,Andrew Grigg,on behalf of the Australasian Leukaemia and Lymphoma Group
Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation
Clinical Trials & Observations
Kenneth P. Micklethwaite,Leighton Clancy,Upinder Sandher,Anna M. Hansen,Emily Blyth,Vicki Antonenas,Mary M. Sartor,Kenneth F. Bradstock,David J. Gottlieb
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy
Clinical Trials & Observations
Michael N. Dworzak,Angela Schumich,Dieter Printz,Ulrike Pötschger,Zvenyslava Husak,Andishe Attarbaschi,Giuseppe Basso,Giuseppe Gaipa,Richard Ratei,Georg Mann,Helmut Gadner
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Clinical Trials & Observations
Carsten Kobe,Markus Dietlein,Jeremy Franklin,Jana Markova,Andreas Lohri,Holger Amthauer,Susanne Klutmann,Wolfram H. Knapp,Josee M. Zijlstra,Andreas Bockisch,Matthias Weckesser,Reinhard Lorenz,Mathias Schreckenberger,Roland Bares,Hans T. Eich,Rolf-Peter Mueller,Michael Fuchs,Peter Borchmann,Harald Schicha,Volker Diehl,Andreas Engert
Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection
Clinical Trials & Observations
Melissa T. Bartman,for the HTLV Outcomes Study (HOST) investigators,Zhanna Kaidarova,for the HTLV Outcomes Study (HOST) investigators,Dale Hirschkorn,for the HTLV Outcomes Study (HOST) investigators,Ronald A. Sacher,for the HTLV Outcomes Study (HOST) investigators,Joy Fridey,for the HTLV Outcomes Study (HOST) investigators,George Garratty,for the HTLV Outcomes Study (HOST) investigators,Joan Gibble,for the HTLV Outcomes Study (HOST) investigators,James W. Smith,for the HTLV Outcomes Study (HOST) investigators,Bruce Newman,for the HTLV Outcomes Study (HOST) investigators,Anthony E. Yeo,for the HTLV Outcomes Study (HOST) investigators,Edward L. Murphy,for the HTLV Outcomes Study (HOST) investigators
Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura
Clinical Trials & Observations
Cindy E. Neunert,for the Intercontinental Childhood ITP Study Group Registry II Participants,George R. Buchanan,for the Intercontinental Childhood ITP Study Group Registry II Participants,Paul Imbach,for the Intercontinental Childhood ITP Study Group Registry II Participants,Paula H. B. Bolton-Maggs,for the Intercontinental Childhood ITP Study Group Registry II Participants,Carolyn M. Bennett,for the Intercontinental Childhood ITP Study Group Registry II Participants,Ellis J. Neufeld,for the Intercontinental Childhood ITP Study Group Registry II Participants,Sara K. Vesely,for the Intercontinental Childhood ITP Study Group Registry II Participants,Leah Adix,for the Intercontinental Childhood ITP Study Group Registry II Participants,Victor S. Blanchette,for the Intercontinental Childhood ITP Study Group Registry II Participants,Thomas Kühne,for the Intercontinental Childhood ITP Study Group Registry II Participants
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Clinical Trials & Observations
Bruno Paiva,Maria-Belén Vidriales,Jorge Cerveró,Gema Mateo,Jose J. Pérez,Maria A. Montalbán,Anna Sureda,Laura Montejano,Norma C. Gutiérrez,Alfonso García de Coca,Natalia de las Heras,Maria V. Mateos,Maria C. López-Berges,Raimundo García-Boyero,Josefina Galende,Jose Hernández,Luis Palomera,Dolores Carrera,Rafael Martínez,Javier de la Rubia,Alejandro Martín,Joan Bladé,Juan J. Lahuerta,Alberto Orfao,Jesús F. San Miguel,on behalf of the GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study groups
HEMATOPOIESIS AND STEM CELLS
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
IMMUNOBIOLOGY
Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiency
Carsten Speckmann,Ulrich Pannicke,Elisabeth Wiech,Klaus Schwarz,Paul Fisch,Wilhelm Friedrich,Tim Niehues,Kimberly Gilmour,Karin Buiting,Michael Schlesier,Hermann Eibel,Jan Rohr,Andrea Superti-Furga,Ute Groß-Wieltsch,Stephan Ehl
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
Stephen A. Beers,Claude H. T. Chan,Sonya James,Ruth R. French,Kathrine E. Attfield,Claire M. Brennan,Anupama Ahuja,Mark J. Shlomchik,Mark S. Cragg,Martin J. Glennie
NEOPLASIA
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia
Jun J. Yang,Deepa Bhojwani,Wenjian Yang,Xiangjun Cai,Gabriele Stocco,Kristine Crews,Jinhua Wang,Debra Morrison,Meenakshi Devidas,Stephen P. Hunger,Cheryl L. Willman,Elizabeth A. Raetz,Ching-hon Pui,William E. Evans,Mary V. Relling,William L. Carroll
The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene
Pin-Yi Wang,Fay Young,Chun-Yu Chen,Brett M. Stevens,Sarah J. Neering,Randall M. Rossi,Timothy Bushnell,Igor Kuzin,David Heinrich,Andrea Bottaro,Craig T. Jordan
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia
Klaus H. Metzeler,for Cancer and Leukemia Group B and the German AML Cooperative Group,Manuela Hummel,for Cancer and Leukemia Group B and the German AML Cooperative Group,Clara D. Bloomfield,for Cancer and Leukemia Group B and the German AML Cooperative Group,Karsten Spiekermann,for Cancer and Leukemia Group B and the German AML Cooperative Group,Jan Braess,for Cancer and Leukemia Group B and the German AML Cooperative Group,Maria-Cristina Sauerland,for Cancer and Leukemia Group B and the German AML Cooperative Group,Achim Heinecke,for Cancer and Leukemia Group B and the German AML Cooperative Group,Michael Radmacher,for Cancer and Leukemia Group B and the German AML Cooperative Group,Guido Marcucci,for Cancer and Leukemia Group B and the German AML Cooperative Group,Susan P. Whitman,for Cancer and Leukemia Group B and the German AML Cooperative Group,Kati Maharry,for Cancer and Leukemia Group B and the German AML Cooperative Group,Peter Paschka,for Cancer and Leukemia Group B and the German AML Cooperative Group,Richard A. Larson,for Cancer and Leukemia Group B and the German AML Cooperative Group,Wolfgang E. Berdel,for Cancer and Leukemia Group B and the German AML Cooperative Group,Thomas Büchner,for Cancer and Leukemia Group B and the German AML Cooperative Group,Bernhard Wörmann,for Cancer and Leukemia Group B and the German AML Cooperative Group,Ulrich Mansmann,for Cancer and Leukemia Group B and the German AML Cooperative Group,Wolfgang Hiddemann,for Cancer and Leukemia Group B and the German AML Cooperative Group,Stefan K. Bohlander,for Cancer and Leukemia Group B and the German AML Cooperative Group,Christian Buske,for Cancer and Leukemia Group B and the German AML Cooperative Group
Activating mutations in human acute megakaryoblastic leukemia
Sébastien Malinge,Christine Ragu,Veronique Della-Valle,Didier Pisani,Stefan N. Constantinescu,Christelle Perez,Jean-Luc Villeval,Dirk Reinhardt,Judith Landman-Parker,Lucienne Michaux,Nicole Dastugue,André Baruchel,William Vainchenker,Jean-Pierre Bourquin,Virginie Penard-Lacronique,Olivier A. Bernard
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma
Wei Xiong,Xiaosong Wu,Sarah Starnes,Sarah K. Johnson,Jeff Haessler,Siqing Wang,Lijuan Chen,Bart Barlogie,John D. Shaughnessy, Jr,Fenghuang Zhan
PHAGOCYTES
RED CELLS
G6PD deficiency, absence of α-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia
Brief Report
Françoise Bernaudin,Suzanne Verlhac,Sylvie Chevret,Martine Torres,Lena Coic,Cécile Arnaud,Annie Kamdem,Isabelle Hau,Maria Grazia Neonato,Christophe Delacourt
TRANSPLANTATION
Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies
Joanne Kurtzberg,Vinod K. Prasad,Shelly L. Carter,John E. Wagner,Lee Ann Baxter-Lowe,Donna Wall,Neena Kapoor,Eva C. Guinan,Stephen A. Feig,Elizabeth L. Wagner,Nancy A. Kernan,on behalf of the COBLT Steering Committee
Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation
Miquel Granell,Álvaro Urbano-Ispizua,Aina Pons,Juan Ignacio Aróstegui,Bernat Gel,Alfons Navarro,Sonia Jansa,Rosa Artells,Anna Gaya,Carme Talarn,Francesc Fernández-Avilés,Carmen Martínez,Montserrat Rovira,Enric Carreras,Ciril Rozman,Manel Juan,Jordi Yagüe,Emili Montserrat,Mariano Monzó
CORRESPONDENCE
-
Cover Image
Cover Image
The X-ray structure of the hemoglobin tetramer. The α-globin chains are shown as blue tubes and the β-globin chains as green tubes. The four heme groups with their central iron atoms are shown in red. These diagrams are based on the drawings of Irving M. Geis. See the article by Alan Schechter beginning on page 3927.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals